Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

Schlieren (Zurich), Switzerland, May 24, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today results from a placebo-controlled, double-blind combined phase I/IIa study with CYT007-TNFQb, a novel vaccine candidate for the treatment of psoriasis and other inflammatory conditions. The present study was a first-time-in-man clinical trial and included 48 patients suffering from moderate to severe plaque psoriasis. In a first part of the study, the safety and tolerability of ascending doses of CYT007-TNFQb were assessed in 24 patients. In the following second part of the study, the exploratory efficacy of the highest vaccine dose was compared to placebo in another 24 patients.

All doses of CYT007-TNFQb tested were safe and well tolerated. All the patients who received the vaccine mounted an antibody response against TNF-?. Exploratory efficacy was assessed according to the Psoriasis Area and Severity Index (PASI), a commonly used measure to evaluate the disease severity in psoriatic patients. The graph below shows the course of the PASI scores throughout the study period (i.e. from baseline up to week 16) for the CYT007-TNFQb-treated and the placebo group.


SEE ATTACHMENT FOR CHART

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented the study results: “The prime objective of this first-time-in-man clinical trial was to demonstrate safety and tolerability of this novel vaccine candidate. This objective was clearly reached. With regard to efficacy we are seeing a temporary improvement of the disease. We will now in detail analyse a broad set of biochemical markers in order to determine whether this observed improvement of disease is indeed treatment related. This additional analytical and laboratory work, which will take several months to complete, will then guide us in the further development of this novel vaccine candidate.”

Cytos Biotechnology will discuss the development program for CYT007-TNFQb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/18/2014)... 18, 2014 MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... that it has entered into a distribution agreement ... provide its dehydrated human amnion/chorion membrane ("dHACM") allograft ... on a private label basis. The ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  Halozyme ... announced that the U.S. Food and Drug Administration ... enrollment and dosing of PEGPH20 in SWOG,s ongoing ... designed to evaluate Halozyme,s investigational drug PEGPH20 (PEGylated ... chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma.  ...
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to the position of  Senior Director of Clinical Development. ... Mr. James has established and led successful global clinical ... , to facilitate the clinical development of numerous ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 2Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 3Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 4Sensitech's Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 11China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 12China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 13China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 14China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 15China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 16China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 17China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 18China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 19China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 20China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 21China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 22China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 23China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 24China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 25China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 26China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results 27
(Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it was ... Indonesia with their son, Isaac, said there was only one choice ... College in 2001 when Thompson was an undergraduate student and needed ... at the time, was French and so she asked him. ... United States when she was 7 years old. Nikel is ...
(Date:9/18/2014)... 18, 2014 Active Aging Week is ... as fully participating members of society and promotes the ... The Stafford – a boutique retirement community located at ... host two screenings of Cyber-Seniors - a humorous and ... residents to watch this great film,” says Thomas Cloutier, ...
(Date:9/18/2014)... cancer experts around the world have issued a plea ... carry out high quality research and clinical trials for ... fatal and for which there are many unanswered questions. ... management of advanced breast cancer, published simultaneously in the ... Annals of Oncology [1] today (Friday), the experts ...
(Date:9/18/2014)... Memorial Cardiac and Vascular Institute ... by performing the first ever, adult heart transplant in ... Organ Sharing) approval to launch the adult heart transplant ... programs in South Florida. , The skilled cardiac ... Medical Director of the Adult Heart Transplant and ...
(Date:9/18/2014)... 19, 2014 A jacket is a ... jacket typically has sleeves, and fastens in the front ... lighter, tighter-fitting, and less insulating than a coat, which ... as protective clothing. Today, Fecbek, a well-known clothing manufacturer ... trendy men’s jackets; all these items are offered at ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Cool Jackets Are For Sale At Fecbek.com 2
... US biomedical engineering team has announced the development of ... an ability to deliver a visual acuity of about ... camera and an ultrasonic distance sensor, both of which ... connect through a cable to a miniature computer which ...
... AIDS research at the moment is the research to treat ... into this project have developed a lot of interest in ... with genes in mind. , ... some people who are infected with the dreaded human immuno-deficiency ...
... may be round the corner as scientists have traced the pathway ... start with they have experimented on the rat brain and they ... time that such advances have been made vis-à-vis eating disorders. ... of brain cells respond to hormones, among them two proteins called ...
... lives of millions, scientists at the University of Scarthclyde and ... protein based drugs such as insulin using inhalers. , ... coated micro crystals can pass through the lung wall and ... those used by asthma sufferers.// , ...
... in the pipeline to reduce risk factors of heart disease, ... attacks. Dr. Carl R. Alving of the Walter Reed Army ... various infectious agents in the development of atherosclerosis, or hardening ... reduce heart disease risk factors such as high cholesterol. ...
... A new breakthrough using gene therapy mouthwash promises good results ... cancer by destroying suspicious growths in the mouth before they ... by unleashing viruses, which kills cells that contain cancer-causing genes. ... is the first study of its kind, scientists are enthusiastic, ...
Cached Medicine News:Health News:Fight oral cancer with gene therapy mouthwash, 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: